SC
CNTX icon

Steven Cohen’s Context Therapeutics CNTX Stock Holding History

Steven Cohen’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-57,231
Closed -$150K – 4088
2026
Q1 		$150K Buy
57,231
+4,530
+9% +$10.6K ﹤0.01% 3567
2025
Q4 		$77.5K Buy
+52,701
New +$61.6K ﹤0.01% 3758

Other funds holding CNTX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Steven Cohen's CNTX Position: Q2 2026 in Review

Steven Cohen sold out of Context Therapeutics (CNTX) in Q2 2026, closing a stake of 57,231 shares — an estimated $150K sold.

Steven Cohen first reported a position in CNTX in Q4 2025 and held it in 2 quarters. The position peaked at $150K in Q1 2026. 79 funds tracked by Wall St. Rank hold CNTX as of Q2 2026.

  • Steven Cohen reported no remaining Context Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Steven Cohen sold 57,231 Context Therapeutics shares in Q2 2026, an estimated $150K.
  • Steven Cohen first reported a position in Context Therapeutics in Q4 2025 and held it in 2 quarters.
  • Steven Cohen's Context Therapeutics position peaked at $150K in Q1 2026.
  • 79 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.